Kumar K V S Hari, Prusty Pitambar
Department of Endocrinology, Command Hospital, Lucknow, Uttar Pradesh, India.
Indian J Endocrinol Metab. 2013 Oct;17(Suppl 1):S139-41. doi: 10.4103/2230-8210.119534.
Prolactinomas are solitary benign neoplasms and resistance to dopamine agonists occur in a small percentage of prolactinomas. Multiple pituitary adenomas are reported in less than 1% of pituitary adenomas and rarely result in resistant prolactinoma. We recently encountered an interesting patient of hyperprolactinemia with multiple pituitary microadenomas. Dopamine agonist use resulted in prolactin normalization and subsequent pregnancy resulted in drug withdrawal. Repeat evaluation after delivery showed a macroprolactinoma and dopamine agonist therapy resulted in biochemical cure without reduction in tumor size. We report the case for its presentation with multiple microadenomas progressing to macroprolactinoma suggesting polyclonal in origin.
催乳素瘤是孤立性良性肿瘤,一小部分催乳素瘤对多巴胺激动剂耐药。在不到1%的垂体腺瘤中报告有多发垂体腺瘤,很少导致耐药性催乳素瘤。我们最近遇到了一名有趣的高催乳素血症患者,患有多发垂体微腺瘤。使用多巴胺激动剂使催乳素恢复正常,随后怀孕导致停药。分娩后复查显示为大催乳素瘤,多巴胺激动剂治疗实现了生化治愈,但肿瘤大小未缩小。我们报告该病例,因其最初表现为多发微腺瘤,随后进展为大催乳素瘤,提示起源于多克隆。